Drug Trial Radar · NCT05841563
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Apr 28, 2023
Primary completion
Dec 30, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- PharmaMarIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phase Ia stage in a framework of more extensive premedication, and to evaluate the antitumor activity of PM54 according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or serum markers as appropriate, in patients with selected advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
PM54Drug
PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54. Route of administration: Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a (dose escalation) and Phase1b (safety run-in): Dose-limiting toxicities (DLTs)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related Adverse Events (AEs)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related deathsTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Serious adverse events (SAEs)Time frame: Screening up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related delaysTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Dose reductionsTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Treatment discontinuationsTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Maximum tolerated dose (MTD)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1a (dose escalation) and Phase1b (safety run-in): Recommended dose (RD)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase1b (safety run-in): Determination of RD with more extensive premedicationTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
- Phase 1b (expansion): Antitumor activityTime frame: Every 6 weeks (± 1 week) in all patients with evaluable disease until Cycle 6. For patients continuing treatment after Cycle 6, assessments performed every 9 weeks (± 1 week) while on treatment, unless otherwise indicated (Up to 48 months)
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
South Texas Accelerated Research Therapeutics
San Antonio, Texas · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
HM Universitario Sanchinarro
Madrid, M, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.